Farxiga approved to reduce risk for CKD progression
Human mesenchymal stem cells show promise in treating chronic lung infections
4 May 2021Do people aged 105 and over live longer because they have more efficient DNA repair?
4 May 2021Farxiga approved to reduce risk for CKD progression
(HealthDay)—Farxiga (dapagliflozin) oral tablets are now approved for adults with chronic kidney disease at risk for disease progression, the U.S. Food and Drug Administration announced Friday.
